Disc Medicine (IRON) Price & Analysis

Compare

504 Followers

IRON Stock Chart & Stats

$89.94

$0.74(1.19%)

At close: Jan 08 4:00 PM EST

$89.94

$0.74(1.19%)

Day’s Range― - ―

52-Week Range$30.82 - $78.17

Previous CloseN/A

Volume41.94K

Average Volume (3M)380.64K

Market Cap

$2.59B

Enterprise Value$1.24B

Total Cash (Recent Filing)$649.97M

Total Debt (Recent Filing)$30.92M

Price to Earnings (P/E)―

Beta1.76

Next Earnings

Nov 06, 2025

EPS Estimate

-1.49

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.58

Shares Outstanding34,765,580

10 Day Avg. Volume400,207

30 Day Avg. Volume380,641

Financial Highlights & Ratios

PEG Ratio-1.01

Price to Book (P/B)3.95

Price to Sales (P/S)0.00

P/FCF Ratio-18.53

Enterprise Value/Market Cap0.48

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-30.90K

Enterprise Value/Ebitda-9.27

Forecast

1Y Price Target

$112.71

Price Target Upside25.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPrevious studies have shown significant improvements in sunlight tolerance for patients using bitopertin, indicating strong treatment efficacy.

Market PotentialEPP is a pan ethnic disorder with an estimated ~20k patients in the U.S., indicating a significant potential market for effective treatments.

Regulatory ApprovalThe FDA announced that bitopertin has been selected as one of the first nine recipients of the Commissioner’s National Priority Review Voucher for the treatment of erythropoietic protoporphyria, accelerating the drug application review timelines to 1-2 months.

Bears Say

Commercialization RiskDisc Medicine has never commercialized a product, which poses a risk for the successful launch and commercialization of bitopertin.

Diagnostic ChallengesA persistent diagnostic gap exists as many pediatricians/dermatologists never order a whole blood protoporphyrin assay, risking underdiagnosis of the disease.

Regulatory ConcernsConcerns exist about the FDA's ability to meet the expedited review timeline due to recent leadership changes and workforce shortages.

Disc Medicine News

Midday Fly By: Apple new F1 broadcast partner, CSX reports Q3 beat

The major averages were higher near noon as the U.S. government shutdown enters its seventeenth day with no...

1d ago

Disc Medicine rises 21.4%

Disc Medicine (IRON) is up 21.4%, or $15.90 to $90.26. Published first on TheFly – the ultimate source...

1d ago

IRON

Disc Medicine rises 25.5%

Disc Medicine (IRON) is up 25.5%, or $18.96 to $93.32. Published first on TheFly – the ultimate source...

1d ago

IRON

Disc Medicine price target raised to $153 from $132 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Disc Medicine (IRON) to $153 from $132 and keeps an...

1d ago

IRON

Disc Medicine price target raised to $108 from $89 at Raymond James

Raymond James raised the firm’s price target on Disc Medicine (IRON) to $108 from $89 and keeps a...

1d ago

IRON

3 Best Stocks to Buy Now, 10/17/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1d ago

APGE

Disc Medicine price target raised to $110 from $90 at Wedbush

Wedbush analyst David Nierengarten raised the firm’s price target on Disc Medicine (IRON) to $110 from $90 and...

1d ago

IRON

Disc Medicine receives CNPV from FDA for Bitopertin

Disc Medicine (IRON) announced that it received a Commissioner’s National Priority Voucher from the U.S. Food and Drug...

2d ago

IRON

Disc Medicine submits NDA to FDA for bitopertin in patients with EPP

Disc Medicine (IRON) announced the submission of a New Drug Application to the U.S. Food and Drug Administration...

18d ago

CHRO

IRON

Disc Medicine Receives FDA Priority Voucher for Bitopertin

Disc Medicine ( ($IRON) ) has shared an announcement. On October 16, 2025, Disc Medicine announced it received...

1d ago

IRON

Promising Outlook for Disc Medicine: Buy Rating Backed by FDA Priority Voucher and Strategic Preparations for Bitopertin Launch

Disc Medicine, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from...

2d ago

IRON

Disc Medicine Board Member Mona Ashiya Resigns

The latest update is out from Disc Medicine ( ($IRON) ). On October 3, 2025, Mona Ashiya, Ph.D.,...

12d ago

IRON

Buy Rating Affirmed for Disc Medicine Amid Promising Bitopertin Prospects in EPP Treatment

Sean Laaman, an analyst from Morgan Stanley, maintained the Buy rating on Disc Medicine. The associated price target...

13d ago

IRON

Promising Developments and Positive Trials Support Buy Rating for Disc Medicine’s Bitopertin

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Disc Medicine. The associated price target...

18d ago

IRON

IRON FAQ

What was Disc Medicine’s price range in the past 12 months?

Disc Medicine lowest stock price was $30.82 and its highest was $78.17 in the past 12 months.

What is Disc Medicine’s market cap?

Disc Medicine’s market cap is $2.59B.

When is Disc Medicine’s upcoming earnings report date?

Disc Medicine’s upcoming earnings report date is Nov 06, 2025 which is in 19 days.

How were Disc Medicine’s earnings last quarter?

Disc Medicine released its earnings results on Aug 07, 2025. The company reported -$1.58 earnings per share for the quarter, missing the consensus estimate of -$1.128 by -$0.452.

Is Disc Medicine overvalued?

According to Wall Street analysts Disc Medicine’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Disc Medicine pay dividends?

Disc Medicine does not currently pay dividends.

What is Disc Medicine’s EPS estimate?

Disc Medicine’s EPS estimate is -1.49.

How many shares outstanding does Disc Medicine have?

Disc Medicine has 34,765,580 shares outstanding.

What happened to Disc Medicine’s price movement after its last earnings report?

Disc Medicine reported an EPS of -$1.58 in its last earnings report, missing expectations of -$1.128. Following the earnings report the stock price went down -3.271%.

Which hedge fund is a major shareholder of Disc Medicine?

Currently, no hedge funds are holding shares in IRON

Disc Medicine Stock Smart Score

Outperform

Fundamentals

Return on Equity

-26.36%

Trailing 12-Months

Asset Growth

30.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Disc Medicine

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Disc Medicine (IRON) Earnings & Revenues

Historic Earnings Reports

IRON Stock 12 Month Forecast

Average Price Target

$112.71

▲(25.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","73":"$73","100":"$100","127":"$127","154":"$154"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":153,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$153.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$112.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,73,100,127,154],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.04,73.6523076923077,80.26461538461538,86.87692307692308,93.48923076923077,100.10153846153847,106.71384615384616,113.32615384615384,119.93846153846154,126.55076923076923,133.16307692307691,139.7753846153846,146.3876923076923,{"y":153,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.04,70.55307692307693,74.06615384615385,77.57923076923078,81.0923076923077,84.60538461538462,88.11846153846153,91.63153846153847,95.14461538461538,98.65769230769232,102.17076923076922,105.68384615384616,109.19692307692307,{"y":112.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.04,68.80615384615385,70.5723076923077,72.33846153846154,74.10461538461539,75.87076923076924,77.63692307692308,79.40307692307692,81.16923076923078,82.93538461538462,84.70153846153846,86.46769230769232,88.23384615384616,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.73,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.13,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >